Clinical trials: Bile Duct Disease
Bile Duct Cancer
Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer
The purpose of this study is to evaluate the safety, tolerability, and immune response of different doses of URLC10 peptide emulsified with Montanide ISA51 in combination with gemcitabine.
- Trial name
- NCT00624182
- Testing
- Peptide vaccine for URLC10, Gemcitabine
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Akita University Hospital
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Primary Biliary Cirrhosis, Liver Inflammation
sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis
Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts.
- Trial name
- NCT02924701
- Testing
- Blood samples, fibroscan and questionaires
- Where
- Denmark
- Volunteers
- 168 people
- Sponsor
- University of Aarhus
Cholecystitis, Cholecystitis; Gallstone
Dutch Cholecystitis Snapshot Study
Background: Cholecystitis is treated by in various types of hospitals by different specialists, and treatment strategy is influenced by logistical and medical reasons and personal preference.
- Conditions
- Cholecystitis, Cholecystitis; Gallstone, Cholecystitis; Choledocholithiasis
- Trial name
- Dutch CHESS (NCT06349863)
- Where
- Netherlands
- Volunteers
- 3,000 people
- Sponsor
- St. Antonius Hospital
Primary Biliary Cholangitis
Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC
Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (OCA) in participants with Primary Biliary Cholangitis (PBC).
- Trial name
- NCT05239468
- Testing
- Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg
- Where
- 26 sites in United States, Argentina and 2 more
- Volunteers
- 72 people
- Sponsor
- Intercept Pharmaceuticals
Anal Cancer, Colorectal Cancer
Interleukin-12 in Treating Patients With Cancer in the Abdomen
RATIONALE: Interleukin-12 may kill tumor cells by stimulating a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 in treating patients with cancer in the abdomen.
- Conditions
- Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer
- Trial name
- NCT00003046
- Testing
- Recombinant Interleukin-12
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Biliary Disease, Pancreatic Disease
Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope
The purpose of the study is to compare the success rates of procedure success and complication rates in patients undergoing Endoscopic retrograde cholangiopancreatography (ERCP) using two types of currently available endoscopes.
- Conditions
- Biliary Disease, Pancreatic Disease, Choledocholithiasis, Biliary Obstruction
- Trial name
- NCT05429203
- Testing
- Duodenoscope with single-use distal cover, Conventional duodenoscope
- Where
- United States
- Volunteers
- 319 people
- Sponsor
- Stanford University
Cholangiopancreatography, Endoscopic Retrograde, Common Bile Duct Calculi
Study of Microbiota in Bile From Patients With Common Bile Duct Stone During ERCP
In this study, investigators will investigate the microbiota of bile in common bile duct stone participants. Three key questions are of concern.
- Conditions
- Cholangiopancreatography, Endoscopic Retrograde, Common Bile Duct Calculi, Microbial Colonization
- Trial name
- NCT03490383
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
ERCP, Choledocholithiasis
Pre-cut Versus Intentional Double Guidewire for ERCP Cannulation: Prospective, Randomized Controlled Trial
Endoscopic retrograde cholangiopancreatography (ERCP) is an indispensable therapeutic procedure in the management of a wide spectrum of pancreaticobiliary disorders, including choledocholithiasis, benign and malignant biliary…
- Conditions
- ERCP, Choledocholithiasis, Biliary Drainage, Biliary Strictures Caused by Malignant Neoplasms
- Trial name
- PRIDE (NCT07329803)
- Testing
- Precut Sphincterotomy, Double Guidewire Technique
- Volunteers
- 840 people
- Sponsor
- Asian Institute of Gastroenterology, India
Primary Biliary Cholangitis (PBC), Long-term Outcomes
PBC Long-term Outcomes Study
Primary biliary cholangitis (PBC) is an autoimmune liver disease predominantly affecting middle-aged women. While historically it was deemed rare, advancements in specific auto-antibody tests have led to increased recognition of…
- Conditions
- Primary Biliary Cholangitis (PBC), Long-term Outcomes, Prognosis, Multicenter Prospective Study
- Trial name
- NCT07149675
- Where
- China
- Volunteers
- 4,000 people
- Sponsor
- Beijing Friendship Hospital
Endoscopic Retrograde Cholangiopancreatography, Common Bile Duct Diseases
Double Guidewire Technique Versus Transpancreatic Precut in Patients With Repetitive Unintentional Cannulation of the Pancreatic Duct.
Difficult cannulation of the common bile duct is encountered in about 10%of ERCP procedures. This frequently happens in the form of repeated unintentional cannulation of the pancreatic duct.
- Conditions
- Endoscopic Retrograde Cholangiopancreatography, Common Bile Duct Diseases, Transpancreatic Precut, Precut
- Trial name
- NCT04503200
- Testing
- Double guidewire, Transpancreatic precut
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Cairo University
Primary Sclerosing Cholangitis
Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis
Primary sclerosing cholangitis (PSC), although uncommon, is a devastating and insidiously progressive liver disease, resulting from advancing inflammation, fibrosis and obliteration of the bile ducts in the liver, leading to…
- Trial name
- NCT01088607
- Testing
- ursodeoxycholic acid (UDCA)
- Where
- 12 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of Tennessee
Cholestasis, Cholestasis of Parenteral Nutrition
Omegaven as Alternative Parenteral Fat Nutrition
To provide Omegaven® as a compassionate treatment for critically ill infants with parenteral nutrition associated cholestasis
- Trial name
- NCT03662282
- Testing
- Omegaven
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of South Florida
Inflammatory Bowel Diseases, Crohn Disease
Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)
This is a prospective observational study collecting long-term clinical data and samples for research in pediatric inflammatory bowel disease (IBD) patients with gut inflammation and a control cohort of pediatric patients with…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Indeterminate Colitis
- Trial name
- STRIDE (NCT06315179)
- Testing
- Esophagogastroduodenoscopy (EGD) with biopsy, Colonoscopy w/ biopsy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Seattle Children's Hospital
Liver Cirrhosis, Biliary
Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment
This Phase 4, randomized, double-blind, placebo-controlled study will evaluate the pharmacokinetics (PK) and safety of OCA treatment in participants with PBC and moderate to severe hepatic impairment over a 48-week treatment…
- Trial name
- NCT03633227
- Testing
- Obeticholic Acid (OCA)
- Where
- 40 sites in United States, Argentina and 10 more
- Volunteers
- 22 people
- Sponsor
- Intercept Pharmaceuticals
Colorectal Adenocarcinoma, Gastric Adenocarcinoma
Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
This is a multi-center, open label, repeat dose, Phase 1 study consisting of a Dose Escalation Phase and a Dose Expansion Phase to evaluate safety, pharmacokinetics, and clinical activity.
- Conditions
- Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Bile Duct Carcinoma
- Trial name
- NCT03507998
- Testing
- CGX1321
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- Curegenix Inc.
Liver Cancer, Anxiety Disorder
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
The study intervention consists of the early integration of palliative care services into standard oncology care in an outpatient setting for patients with advanced lung and non-colorectal gastrointestinal malignancies who are…
- Conditions
- Liver Cancer, Anxiety Disorder, Depression, Small Cell Lung Cancer
- Trial name
- NCT02349412
- Testing
- Early palliative care
- Where
- 23 sites in United States
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Total Parenteral Nutrition-induced Cholestasis
Compassionate Use of Omegaven IV Fat Emulsion
The purpose of the study is to provide use of Omegaven in children with life threatening Total Parenteral Nutrition (TPN) associated cholestasis when all other medical and surgical treatments/therapies have been either…
- Trial name
- NCT01323907
- Testing
- Omegaven IV lipid emulsion
- Where
- United States
- Sponsor
- Sivan Kinberg
Biliary Atresia
Pentoxifylline Therapy in Biliary Atresia
The purpose of this study is to determine whether pentoxifylline reduces liver damage in infants with biliary atresia.
- Trial name
- NCT01774487
- Testing
- Pentoxifylline
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Baylor College of Medicine
Bile Duct Cancer
Combined Treatment of Treated Bile Duct Cancer
The study will evaluate the efficacy and safety of envelizumab in combination with sovalteinib in the treatment of treated bile duct cancer, and explore treatment options to improve patient survival, while the study will attempt…
- Trial name
- CHOL (NCT05911425)
- Testing
- envolizumab , sovalteinib
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.